Trials / Completed
CompletedNCT01334294
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular AMD
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- Notal Vision Ltd. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and paracentral metamorphopsia . The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ForeseeHome | The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration. |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-12-01
- Completion
- 2014-03-01
- First posted
- 2011-04-13
- Last updated
- 2014-10-03
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01334294. Inclusion in this directory is not an endorsement.